Saturday 17 October 2026
Export ABT’s income statement to Excel — free account
Abbott Laboratories
ABT Healthcare Medical Devices
Abbott Laboratories' revenue for fiscal 2025 (year ended December 2025) was $44.3 billion, up 5.67% from fiscal 2024. In the quarter to June 2026, revenue grew 13.0%, EPS fell 47.5%, free cash flow grew 28.9% and total debt rose 142.7%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years; insiders bought in the last twelve months.
104.88
0.20
+0.19%
Follow ABT
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
33.68 | 14.79 | 33.70 | 28.03 | 35.72 | 43.80 | 42.17 | 54.38 | 226.12 | 41.99 |
Piotroski F-Score |
5 | 7 | 6 | 6 | 8 | 6 | 7 | 7 | 4 | 5 |
P/S ratio |
4.92 | 4.69 | 4.77 | 4.40 | 5.80 | 5.61 | 4.81 | 4.16 | 3.73 | 2.77 |
Altman Z-Score |
5.61 | 5.27 | 5.04 | 4.85 | 5.53 | 4.34 | 3.83 | 3.34 | 2.36 | 2.79 |
Altman Z″-Score (non-manufacturers) |
4.85 | 4.72 | 4.24 | 4.19 | 4.06 | 3.39 | 3.05 | 2.99 | 2.85 | 5.16 |
P/FCF ratio |
29.50 | 30.99 | 37.78 | 24.61 | 28.89 | 33.91 | 34.14 | 25.92 | 23.07 | 27.70 |
Beneish M-Score |
(2.50) | (2.09) | (2.47) | (2.68) | (2.66) | (2.56) | (2.59) | (2.71) | (2.05) | (2.95) |
P/Operating CF |
65.80 | 68.62 | 62.92 | 82.59 | 81.45 | 51.11 | 63.56 | 72.04 | 62.37 | 49.30 |
Dividend Safety Score |
62 | — | — | — | — | — | — | — | — | — |
P/B ratio |
4.13 | 4.11 | 4.92 | 5.21 | 6.93 | 5.88 | 4.91 | 4.14 | 3.29 | 2.78 |
Price to Tangible BV |
9.40 | 10.85 | 30.18 | 52.60 | 4,626.18 | 0.00 | 0.00 | 0.00 | 0.00 | 6.79 |
EV/Sales |
5.01 | 4.84 | 4.95 | 4.55 | 5.98 | 5.94 | 5.25 | 4.66 | 4.40 | 2.86 |
EV/EBITDA |
19.89 | 20.21 | 20.42 | 17.09 | 21.53 | 23.67 | 22.18 | 20.47 | 21.90 | 13.11 |
EV/Operating CF |
23.22 | 23.72 | 27.34 | 20.74 | 24.46 | 26.01 | 27.28 | 22.61 | 21.62 | 18.60 |
EV/FCF |
30.04 | 31.96 | 39.24 | 25.46 | 29.79 | 35.90 | 37.21 | 29.03 | 27.15 | 28.62 |
Quick Ratio |
1.02 | 1.05 | 1.00 | 1.06 | 1.28 | 1.14 | 0.88 | 1.03 | 1.67 | 3.31 |
Current Ratio |
1.58 | 1.67 | 1.64 | 1.63 | 1.85 | 1.72 | 1.44 | 1.62 | 2.26 | 4.02 |
Net Debt/EBITDA |
0.36 | 0.61 | 0.76 | 0.57 | 0.65 | 1.31 | 1.83 | 2.20 | 3.29 | 0.42 |
Debt/Assets |
14.91% | 17.35% | 20.05% | 22.53% | 24.00% | 25.55% | 26.42% | 28.83% | 36.35% | 39.27% |
Debt/Equity |
0.25 | 0.29 | 0.38 | 0.45 | 0.50 | 0.56 | 0.57 | 0.63 | 0.89 | 1.00 |
Asset Turnover |
0.53 | 0.54 | 0.54 | 0.58 | 0.58 | 0.49 | 0.47 | 0.43 | 0.42 | 0.44 |
Operating CF/Net income |
1.47 | 0.64 | 1.27 | 1.38 | 1.49 | 1.76 | 1.66 | 2.66 | 11.68 | 2.29 |
Capex/Depreciation |
(0.70) | (0.69) | (0.68) | (0.54) | (0.53) | (0.65) | (0.54) | (0.42) | (0.29) | (0.74) |
Interest Coverage |
16.33 | 12.21 | 10.17 | 14.99 | 15.81 | 9.81 | 6.76 | 4.42 | 1.73 | 7.02 |
| 12.96% | 30.91% | 15.11% | 19.01% | 20.49% | 13.98% | 11.89% | 7.66% | 1.84% | 6.66% | |
| 7.76% | 17.33% | 7.75% | 9.27% | 9.57% | 6.40% | 5.46% | 3.30% | 0.74% | 2.98% | |
ROIC |
8.87% | 7.89% | 8.76% | 12.01% | 12.02% | 7.54% | 6.28% | 4.96% | 1.99% | 8.36% |
Return on Tangible Assets |
30.61% | 66.49% | 30.15% | 36.69% | 35.19% | 25.59% | 28.71% | 17.96% | 2.53% | 5.42% |
Average Days of Receivables |
65.29 | 60.25 | 59.74 | 51.99 | 54.97 | 67.65 | 62.07 | 61.86 | 69.95 | 56.85 |
Research and Development Expense of Revenue |
6.64% | 6.78% | 6.83% | 6.62% | 6.37% | 6.99% | 7.65% | 7.52% | 8.25% | 6.94% |
Selling, General and Administrative Expense of Revenue |
27.82% | 27.88% | 27.30% | 25.77% | 26.29% | 28.02% | 30.61% | 31.87% | 33.52% | 32.30% |
Intangible Assets out of Total Assets |
0.34 | 0.37 | 0.44 | 0.45 | 0.48 | 0.53 | 0.59 | 0.63 | 0.60 | 0.23 |
Share Based Compensation of Revenue |
1.50% | 1.60% | 1.61% | 1.57% | 1.49% | 1.58% | 1.63% | 1.56% | 1.48% | 1.49% |
Graham Net Nets |
(0.04) | (0.05) | (0.06) | (0.06) | (0.06) | (0.10) | (0.14) | (0.17) | (0.24) | (0.09) |
Graham Number |
50.37 | 68.84 | 40.46 | 43.04 | 42.42 | 32.36 | 28.65 | 22.87 | 10.23 | 17.13 |
Earnings Yield |
2.97% | 6.76% | 2.97% | 3.57% | 2.80% | 2.28% | 2.37% | 1.84% | 0.44% | 2.38% |
Free Cash Flow Yield |
3.39% | 3.23% | 2.65% | 4.06% | 3.46% | 2.95% | 2.93% | 3.86% | 4.34% | 3.61% |
Revenue per Share |
25.46 | 24.11 | 23.05 | 24.90 | 24.27 | 19.52 | 18.05 | 17.39 | 15.74 | 14.12 |
Operating CF per Share |
5.49 | 4.92 | 4.17 | 5.47 | 5.93 | 4.46 | 3.47 | 3.58 | 3.20 | 2.17 |
Capex per Share |
(1.25) | (1.27) | (1.27) | (1.01) | (1.06) | (1.23) | (0.93) | (0.79) | (0.65) | (0.76) |
Free Cash Flow per Share |
4.25 | 3.65 | 2.91 | 4.45 | 4.87 | 3.23 | 2.54 | 2.79 | 2.55 | 1.41 |
Cash per Share |
5.13 | 4.58 | 4.18 | 5.80 | 5.77 | 4.03 | 2.34 | 2.32 | 5.52 | 12.71 |
Shareholders Equity per Share |
30.31 | 27.53 | 22.31 | 21.05 | 20.30 | 18.61 | 17.70 | 17.48 | 17.87 | 14.03 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
30.31 | 27.53 | 22.31 | 21.05 | 20.30 | 18.61 | 17.70 | 17.48 | 17.87 | 14.03 |
Free Cash Flow |
7,395.00 | 6,351.00 | 5,059.00 | 7,804.00 | 8,648.00 | 5,724.00 | 4,498.00 | 4,906.00 | 4,435.00 | 2,082.00 |
Working Capital |
9,500.00 | 9,499.00 | 8,829.00 | 9,735.00 | 11,134.00 | 8,534.00 | 4,804.00 | 5,620.00 | 11,235.00 | 20,116.00 |
Capital Expenditures |
(2,171.00) | (2,207.00) | (2,202.00) | (1,777.00) | (1,885.00) | (2,177.00) | (1,638.00) | (1,394.00) | (1,135.00) | (1,121.00) |
Net Current Asset Value |
(7,946.00) | (9,857.00) | (11,717.00) | (12,309.00) | (14,933.00) | (19,104.00) | (20,919.00) | (21,819.00) | (25,005.00) | (5,173.00) |
EV/EBIT |
27.58 | 29.74 | 30.65 | 23.76 | 30.58 | 38.36 | 36.93 | 39.02 | 76.98 | 19.69 |
Capex to Sales |
0.05 | 0.05 | 0.05 | 0.04 | 0.04 | 0.06 | 0.05 | 0.05 | 0.04 | 0.05 |
Price to Operating Income |
27.09 | 28.84 | 29.51 | 22.97 | 29.65 | 36.24 | 33.89 | 34.84 | 65.41 | 19.06 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.26 | 0.30 | 0.32 | 0.36 | 0.39 | 0.37 | 0.38 | 0.44 | 0.52 | 0.27 |
Cash ROIC |
9.91% | 9.07% | 8.32% | 12.22% | 13.44% | 9.75% | 8.43% | 9.06% | 6.48% | 3.46% |
Accounts Receivable Turnover |
5.97 | 6.22 | 6.28 | 6.87 | 6.68 | 5.85 | 6.02 | 5.86 | 6.45 | 6.26 |
Accounts Payable Turnover |
4.58 | 4.41 | 4.04 | 4.25 | 4.44 | 4.17 | 4.25 | 4.73 | 6.93 | 8.05 |
Inventory Turnover |
3.05 | 2.93 | 2.82 | 3.38 | 3.65 | 3.22 | 3.26 | 3.44 | 4.11 | 3.61 |
Average Days of Payables |
80.11 | 81.85 | 87.21 | 87.85 | 86.80 | 96.00 | 89.71 | 85.46 | 70.65 | 47.28 |
Days of Inventory on Hand |
122.58 | 120.86 | 133.41 | 117.71 | 101.54 | 121.93 | 119.06 | 109.05 | 105.92 | 97.69 |
Average Receivables |
7,427.00 | 6,745.00 | 6,391.50 | 6,352.50 | 6,450.50 | 5,919.50 | 5,303.50 | 5,215.50 | 4,248.50 | 3,333.00 |
Average Payables |
4,217.50 | 4,245.00 | 4,451.00 | 4,507.50 | 4,177.00 | 3,599.00 | 3,113.50 | 2,688.50 | 1,790.00 | 1,129.50 |
Average Inventory |
6,341.00 | 6,382.00 | 6,371.50 | 5,665.00 | 5,084.50 | 4,664.00 | 4,056.00 | 3,698.50 | 3,017.50 | 2,516.50 |
Average Assets |
84,063.50 | 77,314.00 | 73,826.00 | 74,817.00 | 73,872.00 | 70,217.50 | 67,530.00 | 71,711.50 | 64,458.00 | 46,956.50 |
Average Common Equity |
50,336.00 | 43,364.00 | 37,866.00 | 36,464.50 | 34,513.50 | 32,152.00 | 31,011.50 | 30,910.00 | 25,907.50 | 21,021.50 |
Columns are period end dates